Aerovate Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Tim Noyes
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 19.1% |
| CEO tenure | 3.5yrs |
| CEO ownership | n/a |
| Management average tenure | 3yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely
Oct 01
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Jun 11Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
May 24Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 09We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate
Oct 17Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Jul 04Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 28A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jan 06Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Oct 14Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
Jul 01We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth
Jan 22Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Sep 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$85m |
| Jun 30 2024 | n/a | n/a | -US$88m |
| Mar 31 2024 | n/a | n/a | -US$82m |
| Dec 31 2023 | US$3m | US$586k | -US$76m |
| Sep 30 2023 | n/a | n/a | -US$70m |
| Jun 30 2023 | n/a | n/a | -US$64m |
| Mar 31 2023 | n/a | n/a | -US$57m |
| Dec 31 2022 | US$704k | US$563k | -US$52m |
| Sep 30 2022 | n/a | n/a | -US$45m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$5m | US$437k | -US$23m |
Compensation vs Market: Tim's total compensation ($USD3.07M) is above average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
CEO
Tim Noyes (62 yo)
3.5yrs
Tenure
US$3,070,657
Compensation
Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.5yrs | US$3.07m | no data | |
| CFO & Treasurer | 3.7yrs | US$2.13m | 0.017% $ 13.4k | |
| Founder | 6.3yrs | US$2.88m | 0.049% $ 37.9k | |
| Chief Scientific Officer | 2.3yrs | US$433.20k | 0.0056% $ 4.3k | |
| Chief Medical Officer | 4.5yrs | US$1.63m | 0.019% $ 14.9k | |
| Head of Regulatory Affairs | 4.2yrs | no data | no data | |
| Executive Vice President of Development Operations | 2.6yrs | no data | no data | |
| Senior Vice President of Quality | 2.3yrs | no data | no data | |
| Executive Vice President of Clinical Development | 1.8yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1.8yrs | no data | no data |
3.0yrs
Average Tenure
61yo
Average Age
Experienced Management: AVTE's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.6yrs | US$3.07m | no data | |
| Independent Director | 1.3yrs | no data | no data | |
| Independent Director | 1.8yrs | US$568.54k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$225.99k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$174.80k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$218.30k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$185.80k | 0% $ 0 | |
| Independent Chairman of the Board | 1.3yrs | US$363.25k | 0% $ 0 |
3.5yrs
Average Tenure
57yo
Average Age
Experienced Board: AVTE's board of directors are considered experienced (3.5 years average tenure).